Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome

Neurology

Volumn 86, Issue 9, 2016, Pages 856-859

  Eller, Michael ^a   Gelfand, Amy A ^a   Riggins, Nina Y ^a   Shiboski, Stephen ^a   Schankin, Christoph ^a   Goadsby, Peter J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE; VASOCONSTRICTOR AGENT;

ADULT; AGE; ARTICLE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSFORMED MIGRAINE; TREATMENT OUTCOME; ADOLESCENT; AGED; CALIFORNIA; CAUSALITY; CHEMICALLY INDUCED; CHRONIC DISEASE; COMORBIDITY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MIGRAINE DISORDERS; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CAUSALITY; CHRONIC DISEASE; COMORBIDITY; DIHYDROERGOTAMINE; FEMALE; HEADACHE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84959550839     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002406     Document Type: Article

References (11)

1. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011; 51(suppl 2): 77-83.
2. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986; 36: 995-997.
3. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine (DHE) for inpatient management of refractory primary headaches. Neurology. 2011; 77: 1827-1832.
4. Weatherall MW, Telzerow AJ, Cittadini E, Kaube H, Goadsby PJ. Intravenous aspirin (lysine acetylsalicylate) in the in-patient management of headache. Neurology. 2010; 75: 1098-1103.
5. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33: 629-808.
6. Perren MJ, Feniuk W, Humphrey PPA. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetised dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol. 1991; 102: 191-197.
7. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986; 26: 168-171.
8. Dahlof CG. How does sumatriptan perform in clinical practice?. Cephalalgia. 1995; 15: 21-28.
9. Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache. 1996; 36: 419-422.
10. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 1993; 629: 95-102.
11. Diener HC, Ferrari M, Mansbach H. Predicting the response to sumatriptan: the sumatriptan naratriptan aggregate patient database. Neurology. 2004; 63: 520-524.